特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
359824

オレキシン受容体1型:パイプライン分析

Orexin Receptor Type 1 - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 80 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
オレキシン受容体1型:パイプライン分析
出版日: 2020年04月30日
発行: Global Markets Direct
ページ情報: 英文 80 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、オレキシン受容体1型を標的とする薬剤の適応症、開発段階、作用機序、投与経路および分子タイプ別の分析、薬剤の薬理作用に関する記述、これまでの研究開発動向、最新のニュースや発表、薬剤の開発に従事している主な企業の概要、休止/中止されたプロジェクトの情報などをお届けします。

イントロダクション

  • 調査範囲

オレキシン受容体1型の概要

治療薬の開発

オレキシン受容体1型:開発中の製品 - 開発段階別

オレキシン受容体1型:開発中の製品 - 治療範囲別

オレキシン受容体1型:開発中の製品 - 適応症別

オレキシン受容体1型:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

オレキシン受容体1型:企業で開発中の製品

オレキシン受容体1型:治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

オレキシン受容体1型の治療薬開発に従事している企業

  • C4X Discovery Holdings PLC
  • エーザイ
  • Hager Biosciences, LLC
  • Heptares Therapeutics Limited
  • Merck & Co., Inc.

薬剤プロファイル

オレキシン受容体1型:休止中のプロジェクト

オレキシン受容体1型:開発が中止された製品

オレキシン受容体1型:主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Chronos Therapeutics Ltd, H1 2020
  • Pipeline by Eisai Co Ltd, H1 2020
  • Pipeline by Eolas Therapeutics Inc, H1 2020
  • Pipeline by Idorsia Pharmaceutical Ltd, H1 2020
  • Pipeline by Indivior Plc, H1 2020
  • Pipeline by Inexia Ltd, H1 2020
  • Pipeline by Johnson & Johnson, H1 2020
  • Pipeline by OXonium Therapeutics, H1 2020
  • Pipeline by Sosei Heptares, H1 2020
  • Pipeline by Yangtze River Pharmaceutical Group, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC2366TDB

Summary:

According to the recently published report 'Orexin Receptor Type 1 - Pipeline Review, H1 2020'; Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 14 molecules.

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in projections from the lateral hypothalamus and is involved in the regulation of feeding behavior. OX1 selectively binds the orexin-A neuropeptide.

The report 'Orexin Receptor Type 1 - Pipeline Review, H1 2020' outlays comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 2, 2, 1, 6 and 1 respectively. Report covers products from therapy areas Central Nervous System and Respiratory which include indications Binge Eating Disorder, Nicotine Addiction, Insomnia, Addiction, Alcohol Addiction, Obstructive Sleep Apnea, Opioid Use Disorder, Anxiety Disorders, Dementia Associated With Alzheimer's Disease, Drug Addiction, Narcolepsy, Panic Disorders, Parkinson's Disease, Pathological Gambling, Sleep Disorders and Smoking Cessation.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)
  • The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Overview
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Companies Involved in Therapeutics Development
  • Chronos Therapeutics Ltd
  • Eisai Co Ltd
  • Eolas Therapeutics Inc
  • Idorsia Pharmaceutical Ltd
  • Indivior Plc
  • Inexia Ltd
  • Johnson & Johnson
  • OXonium Therapeutics
  • Sosei Heptares
  • Yangtze River Pharmaceutical Group
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles
  • ACT-539313 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CT-010018 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CTDP-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EORA-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INDV-2000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JNJ-3215 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lemborexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nemorexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OPN-021 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Mollecules to Antagonize HCRTR1 for Addiction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • suvorexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YZJ-1139 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Products
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 21, 2020: Idorsia's insomnia drug daridorexant passes Phase III study
  • Jan 23, 2020: Eisai: Dayvigo (Lemborexant) approved for treatment of insomnia in Japan
  • Dec 27, 2019: Pivotal phase 3 study of DAYVIGO (lemborexant) for the treatment of insomnia disorder published in JAMA network open
  • Dec 23, 2019: U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for treatment of insomnia in adult patients
  • Dec 10, 2019: Eisai presents new findings on Lemborexant as potential Sleep-Wake disorder therapy at 12th Clinical Trials on Alzheimer's Disease (CTAD) conference
  • Dec 09, 2019: Altasciences to conduct clinical trial for Opioid Use Disorder under NIH funding
  • Dec 02, 2019: Eisai to present latest data on lemborexant at 12th Clinical Trials on Alzheimer's Disease Conference
  • Nov 22, 2019: A sleeping pill that doesn't make you sway: a new targeted insomnia treatment
  • Oct 24, 2019: Trial to test insomnia drug for alcohol use disorder
  • Sep 27, 2019: Three new analyses of data expand understanding of the potential role for investigational agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder
  • Sep 26, 2019: Announcement of National Institutes of Health (NIH) grant award through the NIH helping to end addiction long-term (HEAL) initiative
  • Sep 19, 2019: Eisai to present latest data on Lemborexant at World Sleep Congress
  • Jul 11, 2019: Latest data on Eisai's lemborexant to be presented at Alzheimer's Association International Conference (AAIC) 2019
  • Jun 13, 2019: Efficacy and safety data with Idorsias dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio
  • Jun 11, 2019: Extensive analyses of phase 3 data for investigational Lemborexant assess efficacy and safety profile for the potential treatment of insomnia in adults
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.